Inspire Medical Systems (NYSE:INSP) Given New $85.00 Price Target at Piper Sandler

Inspire Medical Systems (NYSE:INSP) had its price objective trimmed by Piper Sandler from $165.00 to $85.00 in a research note issued to investors on Thursday morning, MarketBeat.com reports. The firm currently has an overweight rating on the stock.

INSP has been the topic of a number of other research reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $130.00 price objective (up previously from $105.00) on shares of Inspire Medical Systems in a report on Tuesday, December 2nd. Oppenheimer downgraded Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 22nd. Wolfe Research upgraded Inspire Medical Systems from a “peer perform” rating to an “outperform” rating and set a $180.00 price target for the company in a research report on Tuesday, November 25th. Royal Bank Of Canada downgraded Inspire Medical Systems from an “outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $175.00 to $90.00 in a research note on Tuesday, January 27th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Inspire Medical Systems in a research note on Monday, December 29th. Six analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $110.65.

Inspire Medical Systems Trading Down 12.4%

INSP stock opened at $59.74 on Thursday. Inspire Medical Systems has a 12-month low of $53.11 and a 12-month high of $197.75. The stock’s 50 day simple moving average is $94.42 and its 200 day simple moving average is $91.48. The firm has a market cap of $1.74 billion, a P/E ratio of 12.00, a P/E/G ratio of 6.88 and a beta of 0.74.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.96. The business had revenue of $269.08 million during the quarter, compared to the consensus estimate of $264.02 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 11.47%. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.15 EPS. On average, research analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares in the company, valued at approximately $3,320,344.08. The trade was a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds and other institutional investors have recently modified their holdings of INSP. Dragoneer Investment Group LLC increased its stake in Inspire Medical Systems by 81.4% during the second quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock valued at $305,532,000 after acquiring an additional 1,056,808 shares during the period. Wasatch Advisors LP raised its holdings in shares of Inspire Medical Systems by 7.2% in the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after buying an additional 110,288 shares in the last quarter. William Blair Investment Management LLC lifted its position in shares of Inspire Medical Systems by 68.7% during the 3rd quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock worth $96,280,000 after buying an additional 528,404 shares during the period. Deerfield Management Company L.P. lifted its position in shares of Inspire Medical Systems by 648.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after buying an additional 907,694 shares during the period. Finally, State Street Corp boosted its stake in Inspire Medical Systems by 2.3% in the 2nd quarter. State Street Corp now owns 1,030,902 shares of the company’s stock valued at $133,780,000 after buying an additional 22,843 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 results beat and operational strength — Inspire posted $269.1M in Q4 revenue (↑12% y/y) and adjusted EPS of $1.65, topping estimates; gross margin expanded and operating cash flow and buybacks support cash returns. Earnings Release
• Neutral Sentiment: Full earnings package and call are available for deeper read — slide deck and transcript provide detail on assumptions behind the 2026 outlook and tax/adjustment impacts for modeling. Slide Deck / Press Release Call Transcript
• Negative Sentiment: Guidance cut and coding/reimbursement uncertainty — management narrowed FY2026 revenue to $950M–$1.0B and said the Inspire V procedure will likely transition to CPT 64582 with a -52 modifier, potentially lowering physician reimbursement and pressuring procedure volumes. That guidance revision is the primary driver of the selloff. MSN: Revenue Outlook & Coding
• Negative Sentiment: Immediate market reaction — analysts and headlines highlighted the coding/guidance risk and shares fell sharply despite the beat. Zacks: Stock Falls Despite Q4 Beat Investing.com: Shares Slide
• Negative Sentiment: Analyst price-target resets — multiple firms lowered targets (Jefferies to $66, Truist to $70, Mizuho to $85, Piper Sandler to $85) which increases near-term downside pressure even when some ratings remain constructive. Benzinga: Analyst Actions The Fly: Mizuho PT Cut
• Negative Sentiment: Bearish analysis and investor concerns — independent commentary highlights lingering risks around reimbursement, growth cadence and margin sustainability, reinforcing the negative sentiment. Seeking Alpha: Critical Take

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.